<DOC>
	<DOCNO>NCT00525265</DOCNO>
	<brief_summary>To investigate pharmacokinetics , pharmacodynamics ( urine volume fluid intake ) , efficacy ( body weight , pulmonary congestion congestion include cardiothoracic ratio ) safety 7-day repeated oral administration OPC-41061 7.5 mg 15 mg congestive heart failure ( cardiac edema ) patient extracellular volume expansion despite use diuretic .</brief_summary>
	<brief_title>A Clinical Pharmacological Study OPC-41061 Treatment Cardiac Edema ( Congestive Heart Failure )</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Edema , Cardiac</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>1 . Subjects cardiac edema receive diuretic treatment 7 day prior start treatment . 2 . Subjects able receive daily regular dosage furosemide 40mg 80mg observation period endoftreatment examination . 3 . CHF patient low limb edema , jugular venous distention , pulmonary congestion due extracellular volume expansion . 4 . Male female subject age 20 85 , inclusive . 5 . Subjects able stay study site day start runin observation period completion postdosing examination 2 . 6 . Subjects capable give informed consent participate study free . 1 . Subjects heart failure markedly fluctuate symptom . 2 . Subjects assist circulation device . 3 . Subjects follow complication symptom : ( 1 ) Suspected decrease circulatory blood flow , ( 2 ) Hypertrophic cardiomyopathy ( dilated phase ) , ( 3 ) Cardiac valve disease significant heart valve stenosis , ( 4 ) Hepatic coma . 4 . Subjects develop acute myocardial infarction within 30 day prior screen examination . 5 . Subjects welldefined diagnosis active myocarditis amyloid cardiomyopathy . 6 . Subjects follow complication symptom : ( 1 ) Diabetes mellitus poorly control blood glucose , ( 2 ) Anuria , ( 3 ) Urination impair due urinary tract stricture , urinary calculus , tumor urinary tract , cause . 7 . Subjects history follow disease : ( 1 ) Sustained ventricular tachycardia ventricular fibrillation within 30 day prior screen examination patient without implanted defibrillator , ( 2 ) Cerebrovascular disorder within 6 month prior screen examination ( asymptomatic cerebral infarction ) , ( 3 ) Hypersensitivity idiosyncratic reaction benzazepine derivative . 8 . Subjects morbidly obese ( body mass index exceed 35 ) . 9 . Subjects systolic blood pressure decubitus position 90 mmHg . 10 . Subjects follow abnormal laboratory value : ( 1 ) Total bilirubin &gt; 3.0 mg/dL , ( 2 ) serum creatinine &gt; 3.0 mg/dL , ( 3 ) serum sodium &gt; 147 mEq/L , ( 4 ) serum potassium &gt; 5.5 mEq/L . 11 . Subjects unable take oral medication . 12 . Female subject pregnant , possibly pregnant , lactate , plan become pregnant . 13 . Subjects receive investigational drug OPC41061 within 30 day prior screen examination . 14 . Subjects previously participate study OPC41061 receive OPC41061 . 15 . Subjects otherwise judge investigator subinvestigator inappropriate inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Vasopressin antagonist</keyword>
	<keyword>Cardiac Edema</keyword>
	<keyword>Diuretics</keyword>
</DOC>